Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease

Bibliography

• Hcmmclgarn BR, Manns BJ, Lloyd A, Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010;303:423-9
   PubMed Web of Science ®Google Scholar
• Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int 2005;99:S52-6
   Google Scholar
• Viberti G, Wheeldon MN.; for the MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8
   PubMed Web of Science ®Google Scholar
• Lewis JE, Hunsicker GL, Clarke RW, Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
   PubMed Web of Science ®Google Scholar
• Jafar TH, Stark PC, Schmid CH, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition, a patient-level meta-analysis. Ann Intern Med 2003;139:244-52
   PubMed Web of Science ®Google Scholar
• Weidmann P, Boehlen LM, Courten M. Effects of different antihypertensive drugs on human proteinuria. Nephrol Dial Transplant 1993;8:582-4
   PubMed Web of Science ®Google Scholar
• Lavermann GD, Henning RH, De Jong PE, Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001;38:1381-4
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertension Res 2009;32:4-107
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC Report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• Mancia G, Backer GD, Dominiczak A, 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Sheinfield GR, Bakris GL. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens 1999;12:80-5
   Web of Science ®Google Scholar
• Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens 2006;24:19-27
   Web of Science ®Google Scholar
• Ertel EA, Campbell KP, Harpold MM, Nomenclature of voltage-gated calcium channels. Neuron 2000;25:533-5
   PubMed Web of Science ®Google Scholar
• Catterall WA. Structure and regulation of voltage-gated Ca2+ channels. Annu Rev Cell Dev Biol 2000;16:521-55
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Homma K, Pathophysiological significance of T-type Ca2+ channels: role of T-type Ca2+ channels in renal microcirculation. J Pharmacol Sci 2005;99:221-7
   PubMed Web of Science ®Google Scholar
• Ohishi M, Takagi T, Ito N, Renal-protective effect of T- and L-type calcium channel blockers in hypertensive patients: an amlodipine-to-benidipine changeover (ABC) study. Hypertens Res 2007;30:797-806
   PubMed Web of Science ®Google Scholar
• Zhou X, Ono H, Ono Y, N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apotosis and proliferation in an I-NAME/SHR model. J Hypertens 2002;20:993-1000
   PubMed Web of Science ®Google Scholar
• Konda T, Enomoto A, Matsushita J, The N- and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a highsucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005;101:1-13
   Google Scholar
• Rose GW, Kanno Y, Ikebukuro H, Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001;24:377-83
   PubMed Web of Science ®Google Scholar
• Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal disease. Hypertens Res 2004;27:379-85
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, African American study of kidney disease and hypertension study group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421-31
   PubMed Web of Science ®Google Scholar
• Roggenenti P, Perna A, Loriga G, REIN-2 study group: blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005;365:939-46
   PubMed Web of Science ®Google Scholar
• Fujita T, Ando K, Nishimura H, Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543-9
   PubMed Web of Science ®Google Scholar
• Morikawa T, Okumura M, Konishi Y, Effects of benidipine on glomerular hemodyanamics and proteinuria in patients with nondiabetic nephropathy. Hypertens Res 2002;25:571-6
   PubMed Web of Science ®Google Scholar
• Abe M, Okada K, Maruyama T, Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009;32:270-5
   PubMed Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-92
   PubMed Web of Science ®Google Scholar
• Bakris GL, Toto RD, McCullough PA, Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008;73:1303-9
   PubMed Web of Science ®Google Scholar
• Bakris GL, Sarafidis PA, Weir MR, Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010;375:1173-81
   PubMed Web of Science ®Google Scholar
• Ishimitsu T, Kameda T, Akashiba A, Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007;30:621-6
   PubMed Web of Science ®Google Scholar
• Yue W, Kimura S, Fujisawa Y, Benidipine dilates both pre- and post-glomerular arteriole in the canine kidney. Hypertens Res 2001;24:429-36
   PubMed Web of Science ®Google Scholar
• Kawata T, Hashimoto S, Koike T. Diversity in the renal hemodynamic effects of dihydropyridine calcium blockers in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997;30:431-6
   PubMed Web of Science ®Google Scholar
• Uneyama H, Uchida H, Konda T, Selectivity of dihydropyridines for cardiac L-type and sympathetic N-type Ca2+ channels. Eur J Pharmacol 1999;373:93-100
   PubMed Web of Science ®Google Scholar
• Murakami M, Mori T, Nakagawasai O, Inhibitory effect of pranidipine on N-type voltage-dependent Ca channels in mice. Neurosci Lett 2004;367:118-22
   PubMed Web of Science ®Google Scholar
• Nap A, Mathy MJ, Balt JC, The evaluation of the N-type channel blocking properties of cilnidipine and other voltage-dependent calcium antagonists. Fund Clin Pharmacol 2004;18:309-19
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N, Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007;100:342-53
   PubMed Web of Science ®Google Scholar
• Nagahama T, Hayashi K, Fujiwara K, Characterization of the renal action of pranidipine in the rat. Arzneimittel Forschung 2000;50:248-53
   PubMed Web of Science ®Google Scholar